JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

198.07 -0.35

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

198

Max

198.64

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.3B

1.3B

Pardavimai

2.1B

15B

P/E

Sektoriaus vid.

92.578

34.393

Pelnas, tenkantis vienai akcijai

2.97

Dividendų pajamingumas

3.31

Pelno marža

9.66

Darbuotojai

55,000

EBITDA

-4.3B

117M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+9.3% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.31%

2.54%

Kitas uždarbis

2025-10-29

Kitas dividendų mokėjimo data

2025-08-15

Kita Ex Dividend data

2025-10-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

12B

348B

Ankstesnė atidarymo kaina

198.42

Ankstesnė uždarymo kaina

198.07

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

AbbVie Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-31 12:46; UTC

Uždarbis

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

2025-06-30 13:02; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

2025-04-25 13:57; UTC

Uždarbis

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

2025-04-25 12:52; UTC

Uždarbis

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

2025-07-31 12:08; UTC

Uždarbis

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

2025-07-31 11:46; UTC

Uždarbis

AbbVie Raises FY Outlook

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q Adj EPS $2.97 >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q EPS 52c >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q Rev $15.42B >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q International HUMIRA Rev $378M >ABBV

2025-07-31 11:44; UTC

Uždarbis

AbbVie 2Q Net $938M >ABBV

2025-06-30 12:47; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

2025-06-30 12:33; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

2025-06-30 12:33; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

2025-06-30 12:32; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

2025-06-30 12:31; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

2025-05-07 09:30; UTC

Svarbiausios naujienos

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

2025-04-28 12:44; UTC

Uždarbis

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025-04-28 09:33; UTC

Uždarbis

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025-04-25 16:03; UTC

Uždarbis

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

2025-04-25 14:00; UTC

Svarbiausios naujienos
Uždarbis

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

2025-04-25 12:24; UTC

Svarbiausios naujienos
Uždarbis

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

2025-04-25 12:03; UTC

Svarbiausios naujienos
Uždarbis

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

2025-04-25 11:43; UTC

Uždarbis

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

2025-04-25 11:43; UTC

Uždarbis

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Akcijų palyginimas

Kainos pokytis

AbbVie Inc Prognozė

Kainos tikslas

By TipRanks

9.3% į viršų

12 mėnesių prognozė

Vidutinis 216.47 USD  9.3%

Aukščiausias 255 USD

Žemiausias 170 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AbbVie Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

17 ratings

11

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

180.37 / 195.54Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.